
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Hanover, N.H. - Tanning beds and lamps could more than doublethe risk of nonmelanoma skin cancers, according to a study conducted byDartmouth Medical Center researchers.